Clinical trials: Insufficient Metabolic Control
Type 2 Diabetes Mellitus
Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin…
- Trial name
- NCT02273050
- Testing
- Saxagliptin 5 mg, Metformin 500 mg with titration
- Where
- 17 sites in China
- Volunteers
- 1,136 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (DM)
A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control
This study will evaluate whether VCT220 tablets improve blood glucose control in adults with type 2 diabetes whose blood glucose remains inadequately controlled with lifestyle intervention alone, metformin alone, or metformin…
- Trial name
- VICTOR-DM (NCT07872436)
- Testing
- VCT220 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Vincentage Pharma Co., Ltd
Type 2 Diabetes Mellitus
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable sulfonylurea alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01590771
- Testing
- Sitagliptin, Gliclazide, Glimepiride
- Volunteers
- 498 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with…
- Trial name
- NCT00859898
- Testing
- Dapagliflozin, Metformin XR
- Where
- 123 sites in United States, India and 4 more
- Volunteers
- 1,093 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone
This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone
- Trial name
- NCT00683657
- Testing
- Saxagliptin
- Where
- 27 sites in United States, Argentina and 6 more
- Volunteers
- 93 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have…
- Trial name
- NCT01137812
- Testing
- Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin
- Where
- 184 sites in United States, Austria and 15 more
- Volunteers
- 756 people
- Sponsor
- Janssen Research & Development, LLC
Type II Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients
To compare the efficacy and safety of ASP1941 + metformin with metformin alone in Asian subjects with type 2 diabetes mellitus.
- Trial name
- NCT01505426
- Testing
- ASP1941, metformin
- Where
- 12 sites in South Korea, Taiwan
- Volunteers
- 171 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes Mellitus
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
This is a study to assess the safety and efficacy of the addition of sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on ipragliflozin, diet, and exercise therapy.
- Trial name
- NCT02577016
- Testing
- Sitagliptin, Ipragliflozin
- Volunteers
- 141 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus Type 2
Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)
A study to evaluate the effectiveness and tolerability of MK0533 and pioglitazone in patients with type 2 diabetes mellitus.
- Trial name
- NCT00543959
- Testing
- MK0533, Comparator: pioglitazone
- Volunteers
- 346 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
To evaluate the efficacy, safety, tolerability, of Saxagliptin (BMS-477118) in combination with Metformin in pediatric patients with type 2 diabetes
- Trial name
- NCT01434186
- Testing
- Metformin IR, Metformin XR, Saxagliptin
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)
This study will evaluate the effect of the addition of metformin once daily (q.d.) or twice daily (b.i.d.) to sitagliptin monotherapy in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic…
- Trial name
- NCT01545388
- Testing
- Sitagliptin, Metformin
- Volunteers
- 337 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Primary Objective: To demonstrate the superiority of Sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control with metformin.
- Trial name
- NCT02926950
- Testing
- Sotagliflozin (SAR439954), Metformin
- Where
- 93 sites in United States, Canada and 2 more
- Volunteers
- 518 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin
The purpose of this study is to determine whether ceasing sitagliptin and switching to exenatide and metformin is non-inferior to adding exenatide to sitagliptin and metformin, in those patients with type 2 diabetes who are…
- Trial name
- NCT00870194
- Testing
- exenatide and sitagliptin
- Where
- 36 sites in Argentina, Australia and 5 more
- Volunteers
- 255 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Comprehensive Add on Study in Japan
The objective of the current study is to investigate the safety and efficacy of linagliptin (5mg / once daily) given for 52 weeks as add-on therapy to patients with type 2 diabetes mellitus and insufficient glycaemic control…
- Trial name
- NCT01204294
- Testing
- Linagliptin, Metformin
- Where
- 43 sites in Japan
- Volunteers
- 574 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
This study will examine the safety and efficacy of once-weekly omarigliptin in participants 18 to <45 years of age with Type 2 diabetes mellitus and inadequate glycemic control.
- Trial name
- NCT01814748
- Testing
- Omarigliptin, Metformin
- Volunteers
- 203 people
- Sponsor
- Merck Sharp & Dohme LLC
Type II Diabetes Mellitus
A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)
A study of different doses of MK-0431 in participants with type 2 diabetes mellitus. There have been 3 extensions to the base study (Extension 1: up to Week 52, Extension 2: up to Week 106, and Extension 3: up to Week 158).
- Trial name
- NCT00481663
- Testing
- Sitagliptin, Metformin, Rescue
- Volunteers
- 555 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
- Trial name
- NCT05666128
- Testing
- HD-6277
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Hyundai Pharm
Type 2 Diabetes Mellitus
A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
The purpose of this study is to assess the hypothesis that treatment with study medication (omarigliptin; MK-3102) provides greater reduction in A1C Hemoglobin (a marker of diabetic severity) compared with placebo, after 12 weeks…
- Trial name
- NCT01217073
- Testing
- Omarigliptin, Pioglitazone, Metformin
- Volunteers
- 685 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Cardiovascular Disease
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with…
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
- Trial name
- NCT01042977
- Testing
- Dapagliflozin
- Where
- 135 sites in United States, Argentina and 8 more
- Volunteers
- 964 people
- Sponsor
- AstraZeneca
Diabetes, Type 2
A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
To determine the effect on glycemic control and lipid parameters of the 2.5 and 5 mg. doses of BMS-298585 in drug naive subjects with Type 2 diabetes as an adjunct to diet and exercise.
- Trial name
- NCT00246987
- Testing
- Muraglitazar
- Where
- 130 sites in United States, Australia and 5 more
- Volunteers
- 341 people
- Sponsor
- Bristol-Myers Squibb